Holen Sie sich die Stockscreener-App
57.42
0.16%
0.355
Schlusskurs vom Vortag:
$57.07
Offen:
$57.53
24-Stunden-Volumen:
120.67K
Relative Volume:
0.11
Marktkapitalisierung:
$9.60B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-519.21M
KGV:
-17.62
EPS:
-3.26
Netto-Cashflow:
$-520.21M
1W Leistung:
-0.36%
1M Leistung:
+19.71%
6M Leistung:
+44.13%
1J Leistung:
+174.95%
1-Tages-Spanne:
$56.50
$58.28
1-Wochen-Bereich:
$53.69
$58.28
52-Wochen-Spanne:
$20.86
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| RVMD | 57.49 | 9.60B | 29.52M | -519.21M | -520.21M | -3.26 |
| VRTX | 447.11 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.93 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.31 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.89 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $61.00 Average Price Target from Brokerages - Defense World
Revolution Medicines executive sells shares worth $977,508 By Investing.com - Investing.com Australia
Revolution Medicines executive sells shares worth $977,508 - Investing.com
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline By Investing.com - Investing.com Australia
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline - Investing.com India
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month HighStill a Buy? - MarketBeat
HC Wainwright Issues Pessimistic Estimate for RVMD Earnings - MarketBeat
What is Wedbush's Forecast for RVMD FY2024 Earnings? - MarketBeat
Revolution Medicines' general counsel sells $360,000 in stock - Investing.com India
Revolution Medicines Stock Soars to All-Time High of $60.53 By Investing.com - Investing.com Canada
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight - Yahoo Finance
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Wellington Management Group LLP Reduces Stake in Revolution Medi - GuruFocus.com
Revolution Medicines' general counsel sells $360,000 in stock By Investing.com - Investing.com UK
Revolution Medicines Stock Soars to All-Time High of $60.53 - Investing.com
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress By Investing.com - Investing.com Australia
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress - Investing.com
HC Wainwright Issues Negative Outlook for RVMD Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus.com
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports Q3 2024 Results and Progress - TipRanks
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark A. Goldsmith sells $3.88 million in stock - Investing.com Canada
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada
(RVMD) Long Term Investment Analysis - Stock Traders Daily
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com South Africa
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times
Revolution Medicines stock hits 52-week high at $51.01 - Investing.com
Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace
Revolution Medicines reports positive RMC-9805 study results - Investing.com India
Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):